DOCSLIB.ORG

Spastic Paraplegia 11 (SPG11): Mutation Spectrum, Phenotype-Genotype Correlations and Functional in Vitro and in Vivo Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Spastic Paraplegia 11 (SPG11): Mutation Spectrum, Phenotype-Genotype Correlations and Functional in Vitro and in Vivo Studies Spastic paraplegia 11 (SPG11): Mutation spectrum, phenotype-genotype correlations and functional in vitro and in vivo studies Giovanni Stevanin, Nadia Soussi-Yanicostas, Elodie Martin, Reena P. Murmu, Sylvain Hanein, Christel Depienne, Emeline Mundwiller, Amir Boukhris, Paola S. Denora, Cyril Goizet, Frédéric Darios, Hamid Azzedine, Agnès Rastetter, Typhaine Esteves, Khalid H. El-Hachimi, Constantin Yanicostas, Alexandra Durr, Alexis Brice: Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière. GHU Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75013 Paris. SPG11 / Neurosciences, Neurologie et Psychiatrie – 2007 programme State of the Art and Aims Expression profiles and subcellular Hereditary spastic paraplegias (HSP) localisation of spatacsin and Spastizin . Characterized by progressive spasticity in lower limbs, . Due to the dysfunction and/or degeneration of the upper motor neuron, Spatacsin and spastizin are proteins: . Pure forms present with pyramidal signs (brisk reflexes, Babinski sign, spasticity, motor deficit, +/- sphincter - expressed with similar profiles in the CNS (Hanein et al, 2008), disturbances) often associated with deep sensory loss, - strongly expressed during development in CNS and non CNS tissues, . Complex forms present with spasticity and numerous combinations of neurological and extra-neurological - with no major colocalisation with a specific cellular compartment, but given their distribution relative to microtubules signs such as ataxia, dysarthria, neuropathy, optic atrophy, retinitis pigmentosa, hearing loss or mental and vesicles, it is tempting to speculate that they play a role in axonal transport. retardation, . Genetic heterogeneity : > 45 loci have been mapped to date. Since partially colocalized with mitochondria, spastizin may have additional mitochondria-based functions. In 2007, identification of 10 different nonsense and frameshift mutations in a novel gene of unknown function, Figure: Intracellular distribution of KIAA1840 (SPG11), which segregated with the disease in 11 autosomal recessive (AR) HSP families. endogenous spatacsin or spastizin in human neuronal-like differentiated SH-SY5Y cells. Aims of the project: Spatacsin and spastizin show partial 1) Establish the spectrum of the mutations or rearrangements in the SPG11 gene by direct sequencing or MLPA in a large Spastizin co-localisations with cytoskeleton (α- collection of ARHSP families and isolated patients, within the European and Mediterranean SPATAX network, α-tubulin tubulin, and with vesicle-like 2) Establish genotype/phenotype correlations, to determine the frequency and nature of SPG11 mutations according to structures (γ adaptin, g,h,i). In blue, the associated phenotype, DAPI. Scale bar: 20 µm. In electron microscopy, spastizin co- 3) Approach the function of the SPG11 gene product (spatacsin) by the identification of partners, the study of its tissue localises partially with vesicle-like and subcellular expression profiles, structures (arrow head) and more 4) Model the disease by RNA interference in Zebrafish. rarely with mitochondria (arrow, colocalisation significant compared to dot distribution in cytosol). Identification of partners of SPG11; ZFYVE26 and KIAA0415, involved in SPG15 and SPG48 Modeling of SPG11 and SPG15 in vivo Identification of truncating mutations in a new gene (ZFYVE26/SPG15) responsible for an SPG11-like phenotype by positional Morpholino oligonucleotide targeting the first coding ATG or splice sites in each of the genes caused abnormal cloning in 3 families linked to chromosome 14 (Hanein et al, 2008). head and tail development associated with locomotor impairment and abnormal branching of spinal cord neurons at Mass spectrometry showed that Spastizin (SPG15) and Spatacsin (SPG11) are members of a common protein complex with the neuromuscular junction. KIAA0415, which is also involved in a new AR-HSP subtype, SPG48 (Slabicki et al, 2010). A Figure (right): In the Tg(Olig2:EGFP) transgenic line staining spinal motor neurons, tetramethylrhodamine conjugated α-bungarotoxin labeling of AchR clusters was used to verify proper differentiation of neuromuscular synapses Figure. KIAA0415 interacts with SPG11, SPG15, KFZp761E198 and C20orf29. (A) SDS-PAGE gels visualized by colocalization of motor axons and AchRs. SPG11 and obtained from the immunoprecipitation of KIAA0415-LAP and SPG11-LAP. Baits (marked in green) and SPG15 morphant embryos show truncated axons (arrows in C, D, and E) prey (marked in black) were identified by in-gel digestion and nanoLC-MS/MS analysis. Bands that are not disturbed axon trajectories; ectopic and aberrant motor axon branches marked represent unspecific background proteins or bait specific proteins. (B) The composition of (arrowheads in C, D, and E) while most AchR clusters are not localized on KIAA0415 protein complex analyzed as established by shotgun-LC-MS/MS. The number of matched axon branches (C’’, D’’, and E’’). Some clusters still colocalize with motor detected peptides and protein sequence coverage are shown. Results for bait proteins are marked in bold. neuron neurites (stars in C’’, D’’, and E’’). Scale bar, 50µm. B (C) Schematic representation of the exon-intron structure of KIAA0415. (D) Pedigree of the SPG48 family and electrophoregram showing the mutation. (Slabicki et al, 2010). C D Figure (Left): (A) Phenotypes of zspg11 and zspg15 morphant embryos, 48 hours post- Relative frequencies, clinical and mutation fecondation (hpf). Whereas embryos injected with 1 pmol of the control mismatch morpholino (MO) were phenotypically undistinguishable from spectra of SPG11 and SPG15 non-injected controls, injection of MO impairs embryonic development of the caudal region. Scale x44. (B) Proportion of deformed embryos following MO injection. The numbers of SPG11 accounts for ~21% of AR-HSP and is a major cause of complicated forms (~50-60% of patients with thin corpus non-injected controls and zspg11 and zspg15 morphant embryos are callosum [TCC] and mental retardation). indicated in parentheses. Each group is compared to its own control group of non-injected siblings. * p< 0.0001. HSP associated with cognitive Pure HSP or SUM TCC and TCC without cognitive impairment with + cases/ cognitive cognitive impairment (MRI not cerebellar tested cases impairment impairment without TCC done) signs (frequency) Conclusions and perspectives 62/97 10/38 6/22 1/30 1/21 80/208 SPG11 is the most frequent form of AR-HSP, (64%) (26%) (27%) (3%) (4%) (38%) SPG11 and SPG15 mutations are associated with mental retardation, peripheral neuropathy and thin corpus callosum at brain MRI, Figure: Brain MRI of a ARHSP-TCC patient Table: Frequency of SPG11 mutations according to the cinical signs in patients Spatacsin (SPG11) and Spastizin (SPG15) are members of the same protein complex and their subcellular expression is showing atrophy of the corpus callosum (left) and (Denora et al, 2009; Stevanin et al, 2008; UF de neurogénétique) white matter hyperintensities (right). compatible with their involvement in intracellular trafficking, Their knock down in zebrafish shows that they are important for proper development of motoneurons, These results call for further studies to understand the contribution of impaired trafficking to the pathology using the zebrafish models and a KO SPG11 model just produced at the Institut Cinique de la souris. Figure: Location of the mutations Publications in SPG11. Note that they are distributed in all exons of the Original articles: gene, which complicates the .Stevanin G, et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain, 131(Pt 3):772-84, 2008. routine diagnosis. .Boukhris A, et al. Hereditary spastic paraplegia with mental impairment and thin corpus callosum in Tunisia: SPG11, SPG15 and further genetic heterogeneity. Arch. Neurol., 65:393-402, 2008. .Hanein S, et al. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal recessive spastic paraplegia including Kjellin syndrome. Am J Hum Genet 2008, 82:992-1002. .Erichsen AK, et al. SPG11, the most common type of recessive spastic paraplegia in Norway? Acta Neurol Scanda 2008, 117 (suppl.188):46-50. .Denora PS, et al. Screening of ARHSP-TCC patients expands the spectrum of SPG11 mutations and includes a large scale gene deletion. Human Mut 2009, 30:E500-E519 .Denora PS, et al. Spastic paraplegia with thinning of the corpus callosum and white matter abnormalities: further mutations and relative frequency of ZFYVE26/SPG15 in the Italian population. J Neurol Scie 2009, 277:22-25. .Boukhris A, et al. Tunisian hereditary spastic paraplegias: clinical variability supported by genetic heterogeneity. Clin Genet 2009,75:527-536. .Goizet C, et al. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology 2009, 73:1111-1119. .Denora PS, et al. Identification of a de novo mutation in SPG11. Mov Disord 2010, 25: 501-503. SPG15 accounts for ~4% of AR-HSP and its frequency in complicated AR-HSP .S łabicki M, et al. A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PloS-Biol 2010,8: e1000408. .Puech B, et al. Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene. Ophthalmol 2011, 118: 564-573. varies from 5% (Italy) to 11% (Continental Europe) and 25% (Tunisia). No .Murmu RP, et
Load more

Recommended publications
  • The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
    The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d.
    [Show full text]
  • Table SI. Genes Upregulated ≥ 2-Fold by MIH 2.4Bl Treatment Affymetrix ID
    Table SI. Genes upregulated 2-fold by MIH 2.4Bl treatment Fold UniGene ID Description Affymetrix ID Entrez Gene Change 1558048_x_at 28.84 Hs.551290 231597_x_at 17.02 Hs.720692 238825_at 10.19 93953 Hs.135167 acidic repeat containing (ACRC) 203821_at 9.82 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 1559509_at 9.41 Hs.656636 202957_at 9.06 3059 Hs.14601 hematopoietic cell-specific Lyn substrate 1 (HCLS1) 202388_at 8.11 5997 Hs.78944 regulator of G-protein signaling 2 (RGS2) 213649_at 7.9 6432 Hs.309090 serine and arginine rich splicing factor 7 (SRSF7) 228262_at 7.83 256714 Hs.127951 MAP7 domain containing 2 (MAP7D2) 38037_at 7.75 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 224549_x_at 7.6 202672_s_at 7.53 467 Hs.460 activating transcription factor 3 (ATF3) 243581_at 6.94 Hs.659284 239203_at 6.9 286006 Hs.396189 leucine rich single-pass membrane protein 1 (LSMEM1) 210800_at 6.7 1678 translocase of inner mitochondrial membrane 8 homolog A (yeast) (TIMM8A) 238956_at 6.48 1943 Hs.741510 ephrin A2 (EFNA2) 242918_at 6.22 4678 Hs.319334 nuclear autoantigenic sperm protein (NASP) 224254_x_at 6.06 243509_at 6 236832_at 5.89 221442 Hs.374076 adenylate cyclase 10, soluble pseudogene 1 (ADCY10P1) 234562_x_at 5.89 Hs.675414 214093_s_at 5.88 8880 Hs.567380; far upstream element binding protein 1 (FUBP1) Hs.707742 223774_at 5.59 677825 Hs.632377 small nucleolar RNA, H/ACA box 44 (SNORA44) 234723_x_at 5.48 Hs.677287 226419_s_at 5.41 6426 Hs.710026; serine and arginine rich splicing factor 1 (SRSF1) Hs.744140 228967_at 5.37
    [Show full text]
  • Anti-KIF13A (Internal Region) Polyclonal Antibody (DPABH-13819) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-KIF13A (internal region) polyclonal antibody (DPABH-13819) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Plus end-directed microtubule-dependent motor protein involved in intracellular transport and regulating various processes such as mannose-6-phosphate receptor (M6PR) transport to the plasma membrane, endosomal sorting during melanosome biogenesis and cytokinesis. Mediates the transport of M6PR-containing vesicles from trans-Golgi network to the plasma membrane via direct interaction with the AP-1 complex. During melanosome maturation, required for delivering melanogenic enzymes from recycling endosomes to nascent melanosomes by creating peripheral recycling endosomal subdomains in melanocytes. Also required for the abcission step in cytokinesis: mediates translocation of ZFYVE26, and possibly TTC19, to the midbody during cytokinesis. Specificity Cross reacts with many mammalian proteins due to sequence homology. Immunogen Synthetic peptide within Human KIF13A (internal sequence). The exact sequence is proprietary.Database link: KIF13A Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Protein A purified Conjugate Unconjugated Applications IHC-P, WB Format Liquid Size 100 μg Buffer Constituents: 1.21% Tris, 0.75% Glycine, 2% Sucrose Preservative None Storage Shipped at 4°C. Store at 4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected]
    [Show full text]
  • Hereditary Spastic Paraplegia: from Genes, Cells and Networks to Novel Pathways for Drug Discovery
    brain sciences Review Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery Alan Mackay-Sim Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia; a.mackay-sim@griffith.edu.au Abstract: Hereditary spastic paraplegia (HSP) is a diverse group of Mendelian genetic disorders affect- ing the upper motor neurons, specifically degeneration of their distal axons in the corticospinal tract. Currently, there are 80 genes or genomic loci (genomic regions for which the causative gene has not been identified) associated with HSP diagnosis. HSP is therefore genetically very heterogeneous. Finding treatments for the HSPs is a daunting task: a rare disease made rarer by so many causative genes and many potential mutations in those genes in individual patients. Personalized medicine through genetic correction may be possible, but impractical as a generalized treatment strategy. The ideal treatments would be small molecules that are effective for people with different causative mutations. This requires identification of disease-associated cell dysfunctions shared across geno- types despite the large number of HSP genes that suggest a wide diversity of molecular and cellular mechanisms. This review highlights the shared dysfunctional phenotypes in patient-derived cells from patients with different causative mutations and uses bioinformatic analyses of the HSP genes to identify novel cell functions as potential targets for future drug treatments for multiple genotypes. Keywords: neurodegeneration; motor neuron disease; spastic paraplegia; endoplasmic reticulum; Citation: Mackay-Sim, A. Hereditary protein-protein interaction network Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery. Brain Sci. 2021, 11, 403.
    [Show full text]
  • Download Ppis for Each Single Seed, Thus Obtaining Each Seed’S Interactome (Ferrari Et Al., 2018)
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.14.425874; this version posted January 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias Nikoleta Vavouraki1,2, James E. Tomkins1, Eleanna Kara3, Henry Houlden3, John Hardy4, Marcus J. Tindall2,5, Patrick A. Lewis1,4,6, Claudia Manzoni1,7* Author Affiliations 1: Department of Pharmacy, University of Reading, Reading, RG6 6AH, United Kingdom 2: Department of Mathematics and Statistics, University of Reading, Reading, RG6 6AH, United Kingdom 3: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 4: Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 5: Institute of Cardiovascular and Metabolic Research, University of Reading, Reading, RG6 6AS, United Kingdom 6: Department of Comparative Biomedical Sciences, Royal Veterinary College, London, NW1 0TU, United Kingdom 7: School of Pharmacy, University College London, London, WC1N 1AX, United Kingdom *Corresponding author: [email protected] Abstract The Hereditary Spastic Paraplegias are a group of neurodegenerative diseases characterized by spasticity and weakness in the lower body. Despite the identification of causative mutations in over 70 genes, the molecular aetiology remains unclear. Due to the combination of genetic diversity and variable clinical presentation, the Hereditary Spastic Paraplegias are a strong candidate for protein- protein interaction network analysis as a tool to understand disease mechanism(s) and to aid functional stratification of phenotypes.
    [Show full text]
  • Comparative Analysis of the Domestic Cat Genome Reveals Genetic Signatures Underlying Feline Biology and Domestication
    Comparative analysis of the domestic cat genome reveals genetic signatures underlying feline biology and domestication Michael J. Montaguea,1, Gang Lib,1, Barbara Gandolfic, Razib Khand, Bronwen L. Akene, Steven M. J. Searlee, Patrick Minxa, LaDeana W. Hilliera, Daniel C. Koboldta, Brian W. Davisb, Carlos A. Driscollf, Christina S. Barrf, Kevin Blackistonef, Javier Quilezg, Belen Lorente-Galdosg, Tomas Marques-Bonetg,h, Can Alkani, Gregg W. C. Thomasj, Matthew W. Hahnj, Marilyn Menotti-Raymondk, Stephen J. O’Brienl,m, Richard K. Wilsona, Leslie A. Lyonsc,2, William J. Murphyb,2, and Wesley C. Warrena,2 aThe Genome Institute, Washington University School of Medicine, St. Louis, MO 63108; bDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine, Texas A&M University, College Station, TX 77843; cDepartment of Veterinary Medicine & Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65201; dPopulation Health & Reproduction, School of Veterinary Medicine, University of California, Davis, CA 95616; eWellcome Trust Sanger Institute, Hinxton CB10 1SA, United Kingdom; fNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20886; gCatalan Institution for Research and Advanced Studies, Institute of Evolutionary Biology, Pompeu Fabra University, 08003 Barcelona, Spain; hCentro de Analisis Genomico 08028, Barcelona, Spain; iDepartment of Computer Engineering, Bilkent University, Ankara 06800, Turkey; jDepartment of Biology, Indiana University, Bloomington,
    [Show full text]
  • Gnomad Lof Supplement
    1 gnomAD supplement gnomAD supplement 1 Data processing 4 Alignment and read processing 4 Variant Calling 4 Coverage information 5 Data processing 5 Sample QC 7 Hard filters 7 Supplementary Table 1 | Sample counts before and after hard and release filters 8 Supplementary Table 2 | Counts by data type and hard filter 9 Platform imputation for exomes 9 Supplementary Table 3 | Exome platform assignments 10 Supplementary Table 4 | Confusion matrix for exome samples with Known platform labels 11 Relatedness filters 11 Supplementary Table 5 | Pair counts by degree of relatedness 12 Supplementary Table 6 | Sample counts by relatedness status 13 Population and subpopulation inference 13 Supplementary Figure 1 | Continental ancestry principal components. 14 Supplementary Table 7 | Population and subpopulation counts 16 Population- and platform-specific filters 16 Supplementary Table 8 | Summary of outliers per population and platform grouping 17 Finalizing samples in the gnomAD v2.1 release 18 Supplementary Table 9 | Sample counts by filtering stage 18 Supplementary Table 10 | Sample counts for genomes and exomes in gnomAD subsets 19 Variant QC 20 Hard filters 20 Random Forest model 20 Features 21 Supplementary Table 11 | Features used in final random forest model 21 Training 22 Supplementary Table 12 | Random forest training examples 22 Evaluation and threshold selection 22 Final variant counts 24 Supplementary Table 13 | Variant counts by filtering status 25 Comparison of whole-exome and whole-genome coverage in coding regions 25 Variant annotation 30 Frequency and context annotation 30 2 Functional annotation 31 Supplementary Table 14 | Variants observed by category in 125,748 exomes 32 Supplementary Figure 5 | Percent observed by methylation.
    [Show full text]
  • FYVE-CENT Antibody A
    Revision 1 C 0 2 - t FYVE-CENT Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 2 3 Web: [email protected] 5 www.cellsignal.com 8 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 285 Rabbit Q68DK2 23503 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity FYVE-CENT Antibody recognizes endogenous levels of total FYVE-CENT protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu595 of human FYVE-CENT protein. Antibodies are purified by protein A and peptide affinity chromatography. Background FYVE-CENT (ZFYVE26) contains an FYVE zinc finger domain characterized by conserved R(R/RK) and HHCRxCG motifs (1). Phosphatidylinositol 3 phosphate binds to FYVE-CENT via the FYVE domain and this binding is crucial in phosphoinositide (PtdIns3P)-regulated cytokinesis (1-3). Research evidence suggests that during cytokinesis, FYVE-CENT directly interacts with TTC19 and is recruited to the midbody by the kinesin protein KIF13A (4). FYVE-CENT may also be involved in the tumor suppressor function of Beclin-1 (5). Researchers have linked the defects in FYVE-CENT to hereditary spastic paraplegia, a condition characterized by deterioration of the corpus callosum of the brain (6).
    [Show full text]
  • Transposon Mutagenesis Identifies Genetic Drivers of Brafv600e Melanoma
    ARTICLES Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma Michael B Mann1,2, Michael A Black3, Devin J Jones1, Jerrold M Ward2,12, Christopher Chin Kuan Yew2,12, Justin Y Newberg1, Adam J Dupuy4, Alistair G Rust5,12, Marcus W Bosenberg6,7, Martin McMahon8,9, Cristin G Print10,11, Neal G Copeland1,2,13 & Nancy A Jenkins1,2,13 Although nearly half of human melanomas harbor oncogenic BRAFV600E mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in BrafV600E mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAFV600E melanoma and discover new genes with potential clinical importance in human melanoma. Substantial sun exposure and numerous genetic factors, including including BrafV600E, recapitulate the genetic and histological hallmarks skin type and family history, are the most important melanoma risk of human melanoma. In these models, increased MEK-ERK signaling factors. Familial melanoma, which accounts for <10% of cases, is asso- initiates clonal expansion of melanocytes, which is limited by oncogene- ciated with mutations in CDKN2A1, MITF2 and POT1 (refs.
    [Show full text]
  • Integrative Functional Analyses of the Neurodegenerative Disease-Associated TECPR2 Gene Reveal Its Diverse Roles
    Integrative functional analyses of the neurodegenerative disease-associated TECPR2 gene reveal its diverse roles Ido Shalev Ben-Gurion University of the Negev Judith Somekh University of Haifa Alal Eran ( [email protected] ) Ben-Gurion University of the Negev https://orcid.org/0000-0001-6784-7597 Research article Keywords: Integrative functional analysis, neurodegenerative disorders, autophagy, ribosome, TECPR2 Posted Date: January 30th, 2020 DOI: https://doi.org/10.21203/rs.2.22274/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/23 Abstract Background Loss of tectonin β-propeller repeat-containing 2 (TECPR2) function has been implicated in an array of neurodegenerative disorders, yet its physiological function remains largely unknown. Understanding TECPR2 function is essential for developing much needed precision therapeutics for TECPR2-related diseases. Methods We leveraged the considerable amounts of functional data to obtain a comprehensive perspective of the role of TECPR2 in health and disease. We integrated expression patterns, population variation, phylogenetic proling, protein-protein interactions, and regulatory network data for a minimally biased multimodal functional analysis. Genes and proteins linked to TECPR2 via multiple lines of evidence were subject to functional enrichment analyses to identify molecular mechanisms involving TECPR2. Results TECPR2 was found to be part of a tight neurodevelopmental gene expression program that includes KIF1A, ATXN1, TOM1L2, and FA2H, all implicated in neurological diseases. Functional enrichment analyses of TECPR2-related genes converged on a role in late autophagy and ribosomal processes. Large-scale population variation data demonstrated that this role is nonredundant. Conclusions TECPR2 might serve as an indicator for the energy balance between protein synthesis and autophagy, and a marker for diseases associated with their imbalance, such as Alzheimer’s disease, Huntington’s disease, and various cancers.
    [Show full text]
  • ZFYVE26 (N-20): Sc-79372
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . ZFYVE26 (N-20): sc-79372 BACKGROUND PRODUCT Zinc finger proteins contain DNA-binding domains and have a wide variety of Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide functions, most of which encompass some form of transcriptional activation and 0.1% gelatin. or repression. ZFYVE26 (zinc finger, FYVE domain containing 26), also known Blocking peptide available for competition studies, sc-79372 P, (100 µg as SPG15, is a 2,539 amino acid protein that exists as multiple alternatively peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). spliced isoforms and contains one FYVE-type zinc finger. Expressed at high levels in brain, prostate, lung, testis, retina, bone marrow and adrenal gland, APPLICATIONS ZFYVE26 is thought to interact with phospholipids in the membrane and may be involved in transcriptional regulation events. Defects in the gene encoding ZFYVE26 (N-20) is recommended for detection of ZFYVE26 of mouse, rat ZFYVE26 are the cause of spastic paraplegia autosomal recessive type 15 and human origin by Western Blotting (starting dilution 1:200, dilution range (SPG15), a neurodegenerative disorder that is characterized by difficulty with 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range balance, weakness and stiffness in the legs, muscle spasms, mental retarda - 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range tion, axonal neuropathy and retinal degeneration. 1:30-1:3000). ZFYVE26 (N-20) is also recommended for detection of ZFYVE26 in additional REFERENCES species, including equine, canine, bovine and porcine.
    [Show full text]
  • Genomics of Asthma, Allergy and Chronic Rhinosinusitis
    Laulajainen‑Hongisto et al. Clin Transl Allergy (2020) 10:45 https://doi.org/10.1186/s13601‑020‑00347‑6 Clinical and Translational Allergy REVIEW Open Access Genomics of asthma, allergy and chronic rhinosinusitis: novel concepts and relevance in airway mucosa Anu Laulajainen‑Hongisto1,2†, Annina Lyly1,3*† , Tanzeela Hanif4, Kishor Dhaygude4, Matti Kankainen5,6,7, Risto Renkonen4,5, Kati Donner6, Pirkko Mattila4,6, Tuomas Jartti8, Jean Bousquet9,10,11, Paula Kauppi3† and Sanna Toppila‑Salmi3,4† Abstract Genome wide association studies (GWASs) have revealed several airway disease‑associated risk loci. Their role in the onset of asthma, allergic rhinitis (AR) or chronic rhinosinusitis (CRS), however, is not yet fully understood. The aim of this review is to evaluate the airway relevance of loci and genes identifed in GWAS studies. GWASs were searched from databases, and a list of loci associating signifcantly (p < 10–8) with asthma, AR and CRS was created. This yielded a total of 267 signifcantly asthma/AR–associated loci from 31 GWASs. No signifcant CRS ‑associated loci were found in this search. A total of 170 protein coding genes were connected to these loci. Of these, 76/170 (44%) showed bronchial epithelial protein expression in stained microscopic fgures of Human Protein Atlas (HPA), and 61/170 (36%) had a literature report of having airway epithelial function. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation analyses were performed, and 19 functional protein categories were found as signif‑ cantly (p < 0.05) enriched among these genes. These were related to cytokine production, cell activation and adaptive immune response, and all were strongly connected in network analysis.
    [Show full text]